H&T Presspart, manufacturer of components for metered dose inhalers (MDIs), has launched collaborative partnership with Hovione Technology to expand its portfolio of drug delivery systems in respiratory care.
As part of the partnership, H&T Presspart has acquired the global rights to manufacture and commercialise a capsule-based dry powder inhaler (DPI) originated by Hovione.
H&T Presspart unveiled an enhanced version of the DPI, which will be marketed as PowdAir Plus, at Respiratory Drug Delivery (RDD) Europe.
Launch of PowdAir Plus
PowdAir Plus is a capsule-based DPI designed for advanced simplicity, ease of use and affordability, making it ideal for developing markets, where demand for respiratory treatments is growing rapidly.
PowdAir Plus's all-plastic, four-component design minimises manufacturing assembly and production costs.
Pharmaceutical companies that work with H&T Presspart on this device can also access Hovione’s expertise in API formulation and manufacturing alongside H&T Presspart’s state- of-the-art manufacturing capabilities and experience in industrialising products for pharmaceutical companies.
DPIs
PowdAir Plus has been developed in response to the recognised need to offer patients in developing markets more choice of DPIs. Most DPIs have been designed for developed markets and incorporate multiple components and complex mechanics.
PowdAir Plus is a complete unit with has no metal or separate parts, and was designed to be robust to withstand the mechanical stresses of frequent use.
Throughout the design process, functionality was of utmost importance and PowdAir Plus delivers an effective dose of medication with each capsule in line with expected market performance. It is compatible with all capsule types (i.e. gelatine and HPMC) in size 3, so can be used with any dry powder medicines.
Unusually, the device opens the capsule once the tray is closed, removing the need for patients to actively pierce the capsule and reducing the number of operational steps.